ПРЕПРИНТ
О результатах, изложенных в препринтах, не следует сообщать в СМИ как о проверенной информации.
Систематизированы данные, полученные в течение предыдущих эпидемий и текущей пандемии, отражающие роль клеточного звена иммунитета в формировании иммунного ответа к коронавирусам. Показано, что коронавирусы запускают в макроорганизме формирование адаптивного иммунитета по гуморальному и клеточному типу. Получены доказательства тому, что синтез специфических иммуноглобулинов еще не свидетельствует о наличии протективного иммунного ответа. Не менее важную роль при этом играет активация клеточного звена иммунитета. Рассмотрены вопросы, касающиеся длительности сохранения специфических клеток памяти к SARS-Cov, MERS -Cov и SARS-Cov-2.
Иванова И. А., Омельченко Н. Д., Филиппенко А. В., Труфанова А. А., Носков А. К. 2021. РОЛЬ КЛЕТОЧНОГО ЗВЕНА ИММУНИТЕТА В ФОРМИРОВАНИИ ИММУННОГО ОТВЕТА ПРИ КОРОНАВИРУСНЫХ ИНФЕКЦИЯХ. COVID19-PREPRINTS.MICROBE.RU. https://doi.org/10.21055/preprints-3111935
1. Костинов М.П., Шмитько А.Д., Полищук В.Б., Хромова Е.А. Современные представления о новом коронавирусе и заболевании, вызванном SARS-COV. Инфекционные болезни: новости, мнения, обучение. 2020, 9 (2): 33–42. DOI: 10.33029/2305-3496-2020-9-2-33-42
2. Пащенков М.В., Хаитов М.Р. Иммунный ответ против эпидемических коронавирусов. Иммунология. 2020, 41 (1): 5–18. DOI: 10.33029/0206-4952-2020-41-1-5-18
3. Смирнов В.С., Тотолян А.А. Врожденный иммунитет при коронавирусной инфекции. Инфекция и иммунитет. 2020, 10 (2): 259–268.
4. Alshukairi A.N., Khalid I., Ahmed W.A., Dada A.M., Bayumi D.T., Malic L.S. et al. Antibody response and disease severity in healthcare worker MERS survivors. Emerg Inf Dis. 2016, 22: 1113–1115. DOI:10.3201/EID2206.160010
5. Al-Tawfiq J.A, Hinedi K, Abbasi S, Babiker M, Sunji A, Eltigani M. Hematologic, hepatic and renal function changes in hospitalized patients with Middle East respiratory syndrome coronavirus. Int J Lab Hematol. 2017, 39 (3): 272–278. DOI: 10.1111/IJLH.12620
6. Cameron M.J., Bermejo-Martin J.F., Danesh A., Muller M.P., Kelvin D.J. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008, 133: 13–19.
7. Chandrashekar A., Liu J., Martinot A. J., McMahan K., Mercado N. B., Peter L. et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science. 2020, 369(6505): 812-817. DOI: 10.1126/science.abc4776
8. Channappanavar R., Zhao J., Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol. Res. 2014, 59(1): 118–128. DOI: 10.1007/s12026-014-8534- z
9. Channappanavar R., Fett C., Zhao J., Meyerholz D.K., Perlman S. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus. Infection J Virol. 2014, 88(19): 11034–11044. DOI: 10.1128/JVI.01505-14
10. Channappanavar R., Fehr A.R., Zheng J., Wohlford-Lenane C., Abrahante J.E., Mack M., Sompallae R., McCray P.B. Jr, Meyerholz D.K., Perlman S. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J. Clin. Invest. 2019, 129 (9): 625–3639. DOI: 10.1172/JCI126363
11. Chen J., Subbarao K. The immunobiology of SARS. Annu Rev Immunol. 2007, 25: 443–472.
12. Chen J., Lau Y. F, Lamirande E.W., Paddock C.D., Bartlett J.H., Zaki S.R., Subbarao K. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c Mice: CD4+ T cells are important in control of SARS-CoV. Infection. J. Virol. 2010, 84(3): 1289–1301. DOI: 10.1128/JVI.01281-09
13. Chu H., Zhou J., Wong B.H., Li C., Chan J.F., Cheng Z.S. et al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J. Infect. Dis. 2016, 213 (6): 904–914. DOI: 10.1093/INFDIS/JIV380
14. Corman V.M., Albarrak A.M., Omrani A.S., Albarrak M.M., Farah M.E., Almasri M., Muth D., Sieberg A., Meyer B., Assiri A.M. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin. Infect. Dis. 2016, 62: 477–483.
15. Cottam E.M., Whelband M.C., Wileman T. Coronavirus NSP6 restricts autophagosome expansion. Autophagy. 2014, 10 (8): 1426–41.
16. de Wit E., van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016, 14(8): 523-534.
17. Deng X., van Geelen A., Buckley A.C., O’Brien A., Pillatzki A., Lager K.M., Faaberg K.S., Baker S.C. Coronavirus endoribonuclease activity in porcine epidemic diarrhea virus suppresses type I and type III interferon responses. J. Virol. 2019, 93 (8): e02000-18.
18. Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L. et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol. 2020: 1–14. DOI: 10.3389/fimmu.2020.00827
19. Drosten C., Meyer B., Muller M.A., Corman V.M., Al-Masri M., Hossain R. et al. Transmission of MERS coronavirus in household contacts. N Engl J Med. 2014, 371: 828–835. DOI:10.1056/NEJMOA1405858
20. Elizaldi S., Lakshmanappa Y.S., Roh J., Schmidt B., Carroll T., Weaver K. et al. SARS-CoV-2 infection induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. Res Sq. Preprint. 2020 Aug 14. DOI: 10.21203/rs.3.rs-51545/v1
21. Enjuanes L., Zuniga S., Castano-Rodriguez C., GutierrezAlvarez J., Canton J., Sola I. Molecular basis of coronavirus virulenceand vaccine development. Adv. Virus Res. 2016, 96: 245–86.
22. Fan Y.-Y., Huang Z.-T., Li L., Wu M.-H., Yu T., Koup R.A., Bailer R.T., Wu C.-Y. Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection. Arch Virol. 2009, 154 (7): 1093–1099. DOI: 10.1007/S00705-009-0409-6
23. Frieman M., Heise M., Baric R. SARS coronavirus and innate immunity. Virus Res. 2008, 133 (1): 101–112. DOI: 10.1016/J.VIRUSRES.2007.03.015
24. Gallais F., Velay A., Wendling M.-J., Nazon C., Partisani M., Sibilia J., Candon S., Fafi-Kremer S. Intrafamilial exposure to SARS-CoV-2 induces cellular immune response without seroconversion. medRxiv 2020.06.21.20132449. Preprint. 22 June 2020. (https://doi.org/10.1101/2020.06.21.20132449)
25. Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N. et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020, 27 (6): 992–1000. DOI: 10.1016/J.CHOM.2020.04.009
26. Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Jennifer M., Moderbacher C.R. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020, 181: 1489–501. DOI: 10.1016/j.cell.2020.05.015
27. Gu J., Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am. J. Pathol. 2007, 170: 1136–1147.
28. Guihot A., Litvinova E., Autran B., Debré P., Vieillard V. Cell-mediated immune responses to COVID-19 infection. Front. Immunol. 2020, 11: 1662. DOI: 10.3389/FIMMU.2020.01662
29. Hajeer A.H., Balkhy H., Johani S., Yousef M.Z., Arabi Y. Association of human leukocyte antigen class II alleles with severe Middle East respiratory syndrome-coronavirus infection. Ann. Thorac. Med. 2016, 11: 211–3. DOI: 10.4103/1817-1737.185756
30. He Z., Zhao C., Dong Q., Zhuang H., Song S., Peng G., Dwyer D.E. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int. J. Infect. 2005, 9: 323–330.
31. Hoffmann M., Kleine-Weber H., Schroeder S., Krüger N., Herrler T, Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020, 181: 271–80.
32. Ka-fai L.C., Wu H., Yan H., Ma S., Wang L, Zhang M. et al. T cell responses to whole SARS coronavirus in humans. J. Immunol. 2008, 181: 5490–500. DOI:10.4049/jimmunol.181.8.5490
33. Kaul D. An overview of coronaviruses including the SARS-2 coronavirus – Molecular biology, epidemiology and clinical implications. Curr. Med. Res. Pract. 2020, 10 (2): 54–64. DOI: 10.1016/J.CMRP.2020.04.001
34. Keicho N., Itoyama S., Kashiwase K., Phi N.C., Long H.T., Ha L.D. et al. Association of human leukocyte antigen class II alleles with severe acute respiratory syndrome in the Vietnamese population. Hum. Immunol. 2009, 70: 527–31. DOI: 10.1016/j.humimm.2009.05.006
35. Kuri-Cervantes L., Pampena M.B., Meng W., Rosenfeld A.M., Ittner C.A.G., Weisman A.R. et al. Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection Version 1. bioRxiv. Preprint. 2020 May 18. DOI: 10.1101/2020.05.18.101717
36. Li G., Fan Y., Lai Y., Han T., Li Z., Zhouet P. et al. Coronavirus infections and immune responses. J. Med. Virol. 2020, 92 (4): 424-32.
37. Li T., Qiu Z., Zhang L., Han Y., He W., Liu Z. et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J. Infect Dis. 2004, 189 (4): 648–651. DOI: 10.1086/381535
38. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003, 426: 450–4.
39. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerging Microbes and Infections. 2020, 9 (4): 1-4. DOI: 10.1080/22221751.2020.1746199
40. Liu J., Li S., Liu J., Liang B., Wang X, Wang H. et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020, 55: 102763. DOI: 10.1016/J.EBIOM.2020.102763
41. Lui P.-Y., Wong L.-Y. R., Fung C.-L., Siu K.-L., Yeung M.-L., Yuen K.-S. et al. Middle East respiratory syndrome corona-virus M protein suppresses type I interferon expression through the inhibition of TBK1-dependent phosphorylation of IRF3. Emerg. Microbes Infect. 2016, 5 (4): e39. DOI: 10.1038/EMI.2016.33
42. Lu G., Hu Y., Wang Q., Qi J., Gao F., Li Y. et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013, 500: 227–231.
43. Mazzoni A., Salvati L., Maggi L., Capone M., Vanni A., Spinicci M. et al. Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J Clin Invest. 2020; 130 (9): 4694-4703. https://doi.org/10.1172/JCI138554.
44. Ng O.W., Chia A., Tan A.T., Jadi R.S., Leong H.N., Bertoletti A. et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016, 34 (17): 2008–14.
45. Ni L., Ye F., Cheng M.-L., Feng Y., Deng Y.-Q., Zhao H. et al.,Detection of SARS-CoV-2-specific humoral and cellular Immunity in COVID-19 convalescent. Individuals Immunity. 2020, 52(6): 971–977. DOI: 10.1016/J.IMMUNI.2020.04.023
46. Novel Coronavirus (2019-nCoV) Situation Report - 11. World Health Organisation (31 января 2020)
47. Oja A. E., Saris A., Ghandour C. A., Kragten N. A. M., Hogema B. M., Nossent L.M. et al. Divergent SARS-CoV-2-specific T and B cell responses in severe but not mild COVID-19. bioRxiv 2020.06.18.159202. Preprint. 18 June 2020. (https://doi.org/10.1101/2020.06.18.159202).
48. Ou X., Liu Y., Lei X., Li P., Mi D., Ren L. Guo L., Guo R., Chen T., Hu J. et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 2020, 11: 1620.
49. Panesar N.S. What caused lymphopenia in SARS and how reliable is the lymphokine status in glucocorticoid-treated patients? Med Hypotheses. 2008; 71 (2): 298–301. DOI: 10.1016/J.MEHY.2008.03.019
50. Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. 2020, 71: 762–8. DOI: 10.1093/cid/ciaa248
51. Rabaan A.A., Al-Ahmed S.H., Haque S., Sah R., Tiwari R., Malik Y.S. et al. SARS-CoV-2, SARS-CoV, and MERS-COV: a comparative overview. Le infezioni in medicina.2020, 28 (2): 174–184.
52. Rokni M., Ghasemi V., Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: Comparison with SARS and MERS. Rev Med Virol. 2020, 30 (3): e2107. DOI: 10.1002/RMV.2107
53. Sariol S. Perlman S. Lessons for COVID-19 Immunity from other coronavirus infections. Immunity. 2020, 53 (2): 248–263. DOI: 10.1016/J.IMMUNI.2020.07.005
54. Sekine T., Perez-Potti A., Rivera-Ballesteros O., Strålin K., Gorin J.-B., Olsson A. et al. COVID-19 study group, robust T cell immunity in convalescent indivi. Kar duals with asymptomatic or mild COVID-19. bioRxiv 2020.06.29.174888. Preprint. 29 June 2020. (https://doi.org/10.1101/2020.06.29.174888).
55. Shah V.K., Firmal P., Alam A., Ganguly D., Chattopadhyay S. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Front Immunol. 2020; 11: 1949. DOI: 10.3389/FIMMU.2020.01949
56. Shin H.-S., Kim Y., Kim G., Lee J.Y., Jeong I., Joh J.-S., Kim H., Chang E., Sim S.Y., Park J.-S., Lim D.G. Immune responses to Middle East respiratory syndrome coronavirus during the acute and convalescent phases of human infection. Clin. Infect. Dis. 2019, 68: 984–992.
57. Tang F., Quan Y., Xin Z.T., Wrammert J., Ma M.J., Lv H., Wang T.B., Yang H., Richardus J.H., Liu W., Cao W.C. Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J. Immunol. 2011, 186: 7264–7268. DOI:10.4049/JIMMUNOL.0903490
58. Thiel V., Weber F. Interferon and cytokine responses to SARS-coronavirus infection Cytokine Growth Factor Rev. 2008, 19 (2): 121–132. DOI: 10.1016/J.CYTOGFR.2008.01.001
59. Thieme C. J., Anft M., Paniskaki K., Blazquez-Navarro A., Doevelaar A., Seibert F. et al. The SARS-CoV-2 T-cell immunity is directed against the spike, membrane, and nucleocapsid protein and associated with COVID 19 severity. medRxiv 2020.05.13.20100636. Preprint. 16 May 2020. (https://doi.org/10.1101/2020.05.13.20100636).
60. Ulrich H., Pillat M. CD147 as a target for COVID-19 treatment: suggested effects of azithromycin and stem cell engagement. Stem Cell Rev Rep. 2020. DOI: 10.1007/S12015-020-09976-7. ONLINE AHEAD OF PRINT.
61. Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. 2020: 1. DOI: 10.1038/S41577-020-0305-6
62. Wan S., Yi Q., Fan S., Lv J., Zhang X., Guo L., Lang C., Xiao Q., Xiao K., Yi Z., Qiang M., Xiang J., Zhang B., Chen Y., Gao C. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID‐19) infected patients. Br J. Haematol. 2020, 189(3): 428–437. DOI: 10.1111/BJH.16659
63. Wang K., Chen W., Zhou Y.S., Lian J.-Q., Zhang Z., Du P. et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. BioRxiv preprint. 2020. DOI: 10.1101/2020.03.14.988345
64. Wang S.F., Chen K.H., Chen M., Li W.Y., Chen Y.J., Tsao C.H. et al. Human-leukocyte antigen class i Cw 1502 and Class II DR 0301 genotypes are associated with resistance to severe acute respiratory syndrome (SARS) infection. Viral Immunol. 2011, 24: 421–6. DOI: 10.1089/vim.2011.0024
65. Wang Y.D., Sin W.Y., Xu G.B., Yang H.H., Wong T.Y., Pang X.W. et al. T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. J. Virol. 2004, 78 (11): 5612–8. DOI: 10.1128/JVI.78.11.5612-5618.2004
66. WHO Director-General’s opening remarks at the media briefing on COVID-19 — 11 March 2020
67. Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020, 367: 1260–1263.
68. Yan R., Zhang Y., Li Y. et al. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020, 367 (6485): 1444-1448. DOI: 10.1126/SCIENCE.ABB2762
69. Yang L.T., Peng H., Zhu Z.L., Li G., Huang Z.T., Zhao Z.X., et al. Long-lived effector/central memory T-cell responses to severe acute respiratory syndrome coronavirus (SARS-CoV) S antigen in recovered SARS patients. Clin. Immunol. 2006; 120 (2):171–8.
70. Yang Y., Xiong Z., Zhang S., Yan Y., Nguyen J., Ng B. et al. Bcl - xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. Biochem. J. 2005, 392 (1): 135–43.
71. Yaqinuddin A. Cross-immunity between respiratory coronaviruses may limit COVID-19 fatalities. Med Hypotheses. 2020; 144: 110049. DOI: 10.1016/J.MEHY.2020.110049
72. Yuan X., Huang W., Ye, B. Chen C., Huang R., Wu F., Wei Q., Zhang W., Hu J. Changes of hematological and immunological parameters in COVID-19 patients. Int. J. Hematol. 2020: 1–7. DOI: 10.1007/S12185-020-02930-W
73. Zhao J., Zhao J., Perlman S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 2010, 84: 9318–9325.
74. Zhao J., Li K., Wohlford-Lenane C., Agnihothram S.S., Fett C., Zhao J., Gale M.J., Jr., Baric R.S., Enjuanes L., Gallagher T., McCray P.B. Perlman S.Rapid generation of a mouse model for Middle East respiratory syndrome. Proc. Natl. Acad. Sci. U S A. 2014, 111 (13): 4970–4975. DOI: 10.1073/PNAS.1323279111
75. Zhao J.J., Zhao A.K., Mangalam .R., Channappanavar C., Fett D.K., Meyerholz S., Agnihothram..R.S., Baric C.S., David S. Perlman Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016, 44(6): 1379–1391. DOI: 10.1016/J.IMMUNI.2016.05.006
76. Zhao J., Alshukairi A.N., Baharoon S.A., Ahmed W.A., Bokhari A.A., Nehdi A.M. et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol. 2017, 2: 5393. DOI:10.1126/SCIIMMUNOL.AAN5393
77. Zhao J., Alshukairi A.N., Baharoon S.A., Ahmed W.A., Bokhari A.A., Nehdi A.M. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020, 52: 971–977.
78. Zheng M., Gao Y., Wang G., Song G., Liu S., Sun D., Xu Y., Tian Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell. Mol. Immunol. 2020, 17(5): 533–535. DOI:10.1038/S41423-020-0402-2
79. Zhou T., Wang H., Luo D., Rowe T., Wang Z., Hogan R.J. et al. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J. Virol. 2004, 78 (13): 7217–26.
80. Zhu Z., Lian X., Su X., Wu W., Marraro G.A., From Z.Y. SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res. 2020, 21: 224. DOI: 10.1186/S12931-020-01479-W
